Screening for coagulation disorders in patients with ischemic stroke
The role of coagulation disorders in the pathogenesis of (recurrent) ischemic stroke is uncertain. Therefore, the clinical utility of screening patients with ischemic stroke for these conditions and the therapeutic implications of a detected coagulation disorder in a patient who experienced ischemic...
Saved in:
Published in | Expert review of neurotherapeutics Vol. 10; no. 8; pp. 1321 - 1329 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Informa Healthcare
01.08.2010
Taylor & Francis Expert Reviews Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The role of coagulation disorders in the pathogenesis of (recurrent) ischemic stroke is uncertain. Therefore, the clinical utility of screening patients with ischemic stroke for these conditions and the therapeutic implications of a detected coagulation disorder in a patient who experienced ischemic stroke are uncertain. We reviewed the currently available data on the relationship between various inherited and acquired coagulation abnormalities (factor V Leiden and prothrombin G20210A mutations, deficiencies of protein C, protein S and anti-thrombin, hyperhomocysteinemia, the antiphospholipid syndrome and increased levels of fibrinogen) and ischemic stroke. Based on the existing evidence we discuss the usefulness of screening stroke patients for prothrombotic conditions and current recommendations regarding the optimal management of ischemic stroke patients in whom a coagulation disorder is found. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Feature-1 |
ISSN: | 1473-7175 1744-8360 |
DOI: | 10.1586/ern.10.104 |